Abstract
The clinical significance of CYP2C19 genetic polymorphism, associated with the violation of the formation of the active clopidogrel metabolite, for efficacy and safety of this drug in cardiology practice is discussed. Approaches to antiplatelet agent choice according to pharmacogenetic CYP2C19 testing, as well as the indications for this approach use in clinical practice are presented. Consideration of these testing results should increase the efficacy and safety of antiplatelet treatment.
Highlights
The clinical significance of CYP2C19 genetic polymorphism, associated with the violation of the formation of the active clopidogrel metabolite, for efficacy and safety of this drug in cardiology practice is discussed
Сеченова Сычев Дмитрий Алексеевич – д.м.н., профессор кафедры клинической фармакологии и пропедевтики внутренних болезней Первого МГМУ им
Сеченова Прокофьев Алексей Борисович – д.м.н., профессор кафедры клинической фармакологии и пропедевтики внутренних болезней Первого МГМУ им
Summary
The clinical significance of CYP2C19 genetic polymorphism, associated with the violation of the formation of the active clopidogrel metabolite, for efficacy and safety of this drug in cardiology practice is discussed. Рассматривают клиническое значение генетического полиморфизма CYP2C19, ассоциированного с нарушением образования активного метаболита клопидогрела, для эффективности и безопасности данного препарата у пациентов кардиологического профиля. Обсуждают тактику выбора антиагрегантов по результатам фармакогенетического тестирования пациентов по CYP2C19, а также показания для применения подобного подхода в клинической практике, что должно повысить эффективность и безопасность лечения.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
